Cardio & Vascular weakness - Co said Cardio & Vascular sales fell 2% due to the impact from two new Electrophysiology products
Other Markets decline - Co attributed 43% drop in Other Markets sales to exit from Portable Medical market
Restructuring and impairment costs - Co recorded fixed asset impairment charges and restructuring expenses, affecting operating income
Outlook withdrawn
Integer is withdrawing its previously issued financial outlook due to pending acquisition by KKR
Key details and analyst coverage
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$464 mln
$450.50 mln (9 Analysts)
Q2 Adjusted EPS
Beat
$1.60
$1.41 (8 Analysts)
Q2 EPS
$0.69
Q2 Adjusted Net Income
Beat
$55 mln
$48.17 mln (7 Analysts)
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
ITGR•
